ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.546,62
-0,88%
S&P 500
5.266,42
-0,76%
US Dollar vs BRL
5,1552
0,05%
Bitcoin
67.064,63
-2,95%
Brent Oil
81,185
-0,42%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Insys Therapeutics, Inc. (INSY)

  7. Insys Therapeutics, Inc. (INSY) Notícias

INSY

INSYS THERAPEUTICS, INC. (INSY)

Insys Therapeutics, Inc.
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:INSY
DataHoraFonteTítuloCódigoCompanhia
04/11/201908:08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INSYInsys Therapeutics, Inc.
08/08/201918:19Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:INSYInsys Therapeutics, Inc.
03/07/201907:00GlobeNewswire Inc.FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspe...NASDAQ:INSYInsys Therapeutics, Inc.
24/06/201910:38Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:INSYInsys Therapeutics, Inc.
12/06/201909:00GlobeNewswire Inc.INSYS Therapeutics, Inc. Receives Court Approval of “First Day” MotionsNASDAQ:INSYInsys Therapeutics, Inc.
10/06/201910:32Dow Jones NewsStocks to Watch: Salesforce.com, Insys, United Technologies, Barnes & Noble, Dunkin' Brands, and MoreNASDAQ:INSYInsys Therapeutics, Inc.
10/06/201907:07GlobeNewswire Inc.INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy LiabilitiesNASDAQ:INSYInsys Therapeutics, Inc.
07/06/201915:10Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:INSYInsys Therapeutics, Inc.
06/06/201918:13Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INSYInsys Therapeutics, Inc.
06/06/201918:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:INSYInsys Therapeutics, Inc.
13/05/201907:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:INSYInsys Therapeutics, Inc.
10/05/201920:05GlobeNewswire Inc.INSYS Therapeutics Reports First Quarter 2019 ResultsNASDAQ:INSYInsys Therapeutics, Inc.
30/04/201917:24Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:INSYInsys Therapeutics, Inc.
29/04/201913:38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:INSYInsys Therapeutics, Inc.
15/04/201909:30GlobeNewswire Inc.INSYS Therapeutics Implements Leadership ChangesNASDAQ:INSYInsys Therapeutics, Inc.
08/04/201909:30GlobeNewswire Inc.Report: Exploring Fundamental Drivers Behind Zscaler, Golden Star Resources, Flexion Therapeutics, SP Plus, Insys Therapeutic...NASDAQ:INSYInsys Therapeutics, Inc.
25/03/201907:00GlobeNewswire Inc.INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Dru...NASDAQ:INSYInsys Therapeutics, Inc.
13/03/201907:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:INSYInsys Therapeutics, Inc.
07/03/201918:15GlobeNewswire Inc.INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 ResultsNASDAQ:INSYInsys Therapeutics, Inc.
06/03/201918:15GlobeNewswire Inc.INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7NASDAQ:INSYInsys Therapeutics, Inc.
25/02/201908:00GlobeNewswire Inc.INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment o...NASDAQ:INSYInsys Therapeutics, Inc.
19/02/201916:07Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:INSYInsys Therapeutics, Inc.
09/01/201909:00GlobeNewswire Inc.INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of AnaphylaxisNASDAQ:INSYInsys Therapeutics, Inc.
03/01/201909:00GlobeNewswire Inc.INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare ConferenceNASDAQ:INSYInsys Therapeutics, Inc.
18/12/201809:00GlobeNewswire Inc.INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of NaloxoneNASDAQ:INSYInsys Therapeutics, Inc.
17/12/201809:00GlobeNewswire Inc.INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannab...NASDAQ:INSYInsys Therapeutics, Inc.
04/12/201809:00GlobeNewswire Inc.INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epile...NASDAQ:INSYInsys Therapeutics, Inc.
20/11/201810:00GlobeNewswire Inc.Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented...NASDAQ:INSYInsys Therapeutics, Inc.
06/11/201811:45InvestorWireAs the Cannabis Industry Grows, So Do Challenges of Supply and DistributionNASDAQ:INSYInsys Therapeutics, Inc.
05/11/201819:16GlobeNewswire Inc.INSYS Therapeutics Reports Third Quarter 2018 ResultsNASDAQ:INSYInsys Therapeutics, Inc.
 Apresentando as notícias mais relevantes sobre:NASDAQ:INSY

Seu Histórico Recente

BIT
P1YX54
NLBNPIT1YX54 20991231 17...
TSXV
ELM
Element Lifestyle Retire...
ASE
INTEKB1
Ideal
COIN
MODDETH
Modefi
BIT
P20RJ6
NLBNPIT20RJ6 20991231 20...
NASDAQI
TRESTATNGBP
Strategic Technology & E...
AMEX
CRC
Chromcraft Revington
TSX
MGA
Mega Uranium
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados